iShares Neuroscience and Healthcare ETF
IBRN
4 hedge funds and large institutions have $3.21M invested in iShares Neuroscience and Healthcare ETF in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
5% less capital invested
Capital invested by funds: $3.38M → $3.21M (-$166K)
2.14% less ownership
Funds ownership: 85.89% → 83.75% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$58K |
| 2 |
Jane Street
New York
|
+$28.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
-$169K |
IBRN Hedge Fund Activity: Q1 2024 in Review
4 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in iShares Neuroscience and Healthcare ETF (IBRN) for Q1 2024, worth a combined $3.21M — down 4.9% from $3.38M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new IBRN positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $58K. The largest seller was Flow Traders U.S., cutting an estimated $169K.
- 4 institutional investors held iShares Neuroscience and Healthcare ETF (IBRN) as of Q1 2024, up from 3 in Q4 2023.
- Funds reported $3.21M of iShares Neuroscience and Healthcare ETF stock for Q1 2024, down 4.9% quarter-over-quarter.
- 1 fund opened new iShares Neuroscience and Healthcare ETF positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest iShares Neuroscience and Healthcare ETF buyer in Q1 2024 was Bank of Montreal, an estimated $58K added.
- The largest iShares Neuroscience and Healthcare ETF seller in Q1 2024 was Flow Traders U.S., an estimated $169K sold.
Based on aggregated 13F filings for Q1 2024.